Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WGI-2101
- Development stage
- Preclinical
- Lead developer
- WhiteOak Group
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
WGI-2101 (MyMiR) is an anti-microRNA therapeutic candidate being developed by The WhiteOak Group for the treatment of non-small-cell lung cancer (NSCLC). The drug is designed to inhibit microRNA-21 (miR-21), an oncogenic microRNA that is frequently upregulated in solid tumors and plays a critical role in promoting cell proliferation, survival, and invasion while suppressing apoptosis. WGI-2101 utilizes a proprietary lipid nanoparticle (LNP) delivery platform called QTsome to protect the anti-microRNA payload from degradation and enhance its delivery to tumor cells. The program is currently in the preclinical stage, with IND-enabling studies underway to support future clinical trials.
- Brand names
- MyMiR
02
Targets
miR-21 (MicroRNA-21)
Beyond the preview
Go deeper on WGI-2101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WGI-2101.